162 related articles for article (PubMed ID: 31530630)
21. Specific inhibition of c-sis protein synthesis and cell proliferation with antisense oligodeoxynucleotides in human glioma cells.
Nitta T; Sato K
Neurosurgery; 1994 Feb; 34(2):309-14; discussion 314-5. PubMed ID: 8177392
[TBL] [Abstract][Full Text] [Related]
22. Treatment of malignant gliomas with TGF-beta2 antisense oligonucleotides.
Hau P; Jachimczak P; Bogdahn U
Expert Rev Anticancer Ther; 2009 Nov; 9(11):1663-74. PubMed ID: 19895249
[TBL] [Abstract][Full Text] [Related]
23. Suppression of glioblastoma cell growth following antisense oligonucleotide-mediated inhibition of fibroblast growth factor receptor expression.
Yamada SM; Yamaguchi F; Brown R; Berger MS; Morrison RS
Glia; 1999 Oct; 28(1):66-76. PubMed ID: 10498824
[TBL] [Abstract][Full Text] [Related]
24. Downregulation of laminin alpha4 chain expression inhibits glioma invasion in vitro and in vivo.
Nagato S; Nakagawa K; Harada H; Kohno S; Fujiwara H; Sekiguchi K; Ohue S; Iwata S; Ohnishi T
Int J Cancer; 2005 Oct; 117(1):41-50. PubMed ID: 15915502
[TBL] [Abstract][Full Text] [Related]
25. Endothelium-dependent epithelial-mesenchymal transition of tumor cells: exclusive roles of transforming growth factor β1 and β2.
Kimura C; Hayashi M; Mizuno Y; Oike M
Biochim Biophys Acta; 2013 Oct; 1830(10):4470-81. PubMed ID: 23668958
[TBL] [Abstract][Full Text] [Related]
26. Autocrine VEGFR1 and VEGFR2 signaling promotes survival in human glioblastoma models in vitro and in vivo.
Szabo E; Schneider H; Seystahl K; Rushing EJ; Herting F; Weidner KM; Weller M
Neuro Oncol; 2016 Sep; 18(9):1242-52. PubMed ID: 27009237
[TBL] [Abstract][Full Text] [Related]
27. An imbalance between Smad and MAPK pathways is responsible for TGF-beta tumor promoting effects in high-grade gliomas.
Nickl-Jockschat T; Arslan F; Doerfelt A; Bogdahn U; Bosserhoff A; Hau P
Int J Oncol; 2007 Feb; 30(2):499-507. PubMed ID: 17203233
[TBL] [Abstract][Full Text] [Related]
28. Participation of an abnormality in the transforming growth factor-beta signaling pathway in resistance of malignant glioma cells to growth inhibition induced by that factor.
Zhang L; Sato E; Amagasaki K; Nakao A; Naganuma H
J Neurosurg; 2006 Jul; 105(1):119-28. PubMed ID: 16871886
[TBL] [Abstract][Full Text] [Related]
29. Fibroblast growth factor 13 regulates glioma cell invasion and is important for bevacizumab-induced glioma invasion.
Otani Y; Ichikawa T; Kurozumi K; Inoue S; Ishida J; Oka T; Shimizu T; Tomita Y; Hattori Y; Uneda A; Matsumoto Y; Michiue H; Date I
Oncogene; 2018 Feb; 37(6):777-786. PubMed ID: 29059154
[TBL] [Abstract][Full Text] [Related]
30. Costimulatory protein 4IgB7H3 drives the malignant phenotype of glioblastoma by mediating immune escape and invasiveness.
Lemke D; Pfenning PN; Sahm F; Klein AC; Kempf T; Warnken U; Schnölzer M; Tudoran R; Weller M; Platten M; Wick W
Clin Cancer Res; 2012 Jan; 18(1):105-17. PubMed ID: 22080438
[TBL] [Abstract][Full Text] [Related]
31. Knockdown of Long Noncoding RNA Plasmacytoma Variant Translocation 1 with Antisense Locked Nucleic Acid GapmeRs Exerts Tumor-Suppressive Functions in Human Acute Erythroleukemia Cells Through Downregulation of
Salehi M; Sharifi M; Bagheri M
Cancer Biother Radiopharm; 2019 Aug; 34(6):371-379. PubMed ID: 30141968
[No Abstract] [Full Text] [Related]
32. TGF-beta2 inhibition augments the effect of tumor vaccine and improves the survival of animals with pre-established brain tumors.
Liu Y; Wang Q; Kleinschmidt-DeMasters BK; Franzusoff A; Ng KY; Lillehei KO
J Neurooncol; 2007 Jan; 81(2):149-62. PubMed ID: 16941073
[TBL] [Abstract][Full Text] [Related]
33. SYK inhibition blocks proliferation and migration of glioma cells and modifies the tumor microenvironment.
Moncayo G; Grzmil M; Smirnova T; Zmarz P; Huber RM; Hynx D; Kohler H; Wang Y; Hotz HR; Hynes NE; Keller G; Frank S; Merlo A; Hemmings BA
Neuro Oncol; 2018 Apr; 20(5):621-631. PubMed ID: 29401256
[TBL] [Abstract][Full Text] [Related]
34. Trabedersen, a TGFbeta2-specific antisense oligonucleotide for the treatment of malignant gliomas and other tumors overexpressing TGFbeta2.
Vallières L
IDrugs; 2009 Jul; 12(7):445-53. PubMed ID: 19579166
[TBL] [Abstract][Full Text] [Related]
35. Antisense oligonucleotides specific for transforming growth factor beta2 inhibit the growth of malignant mesothelioma both in vitro and in vivo.
Marzo AL; Fitzpatrick DR; Robinson BW; Scott B
Cancer Res; 1997 Aug; 57(15):3200-7. PubMed ID: 9242450
[TBL] [Abstract][Full Text] [Related]
36. Deletion of Mediator 1 suppresses TGFβ signaling leading to changes in epidermal lineages and regeneration.
Oda Y; Nguyen T; Hata A; Meyer MB; Pike JW; Bikle DD
PLoS One; 2020; 15(8):e0238076. PubMed ID: 32857768
[TBL] [Abstract][Full Text] [Related]
37. Antisense oligonucleotide targeting CD39 improves anti-tumor T cell immunity.
Kashyap AS; Thelemann T; Klar R; Kallert SM; Festag J; Buchi M; Hinterwimmer L; Schell M; Michel S; Jaschinski F; Zippelius A
J Immunother Cancer; 2019 Mar; 7(1):67. PubMed ID: 30871609
[TBL] [Abstract][Full Text] [Related]
38. Glioma cell invasion: regulation of metalloproteinase activity by TGF-beta.
Wick W; Platten M; Weller M
J Neurooncol; 2001 Jun; 53(2):177-85. PubMed ID: 11716069
[TBL] [Abstract][Full Text] [Related]
39. Experimental therapy of human prostate cancer by inhibiting MDM2 expression with novel mixed-backbone antisense oligonucleotides: in vitro and in vivo activities and mechanisms.
Wang H; Yu D; Agrawal S; Zhang R
Prostate; 2003 Feb; 54(3):194-205. PubMed ID: 12518324
[TBL] [Abstract][Full Text] [Related]
40. Silencing of transforming growth factor-beta1 in situ by RNA interference for breast cancer: implications for proliferation and migration in vitro and metastasis in vivo.
Moore LD; Isayeva T; Siegal GP; Ponnazhagan S
Clin Cancer Res; 2008 Aug; 14(15):4961-70. PubMed ID: 18676771
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
